Sonoma Pharmaceuticals, Inc.
SNOA
$1.33
$0.010.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 59.55% | 48.14% | 22.03% | 56.58% | 18.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.55% | 48.14% | 22.03% | 56.58% | 18.40% |
| Cost of Revenue | 50.10% | 51.84% | 17.65% | 57.08% | 22.35% |
| Gross Profit | 76.02% | 42.74% | 29.92% | 55.77% | 12.10% |
| SG&A Expenses | 2.80% | 12.07% | -5.50% | 10.38% | -2.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.14% | 34.06% | 9.40% | 34.14% | 11.96% |
| Operating Income | 96.35% | 46.49% | 34.24% | 60.35% | 6.65% |
| Income Before Tax | 73.43% | 5.87% | -3.26% | -57.88% | -24.57% |
| Income Tax Expenses | -- | -66.13% | -1,544.44% | -234.01% | -100.68% |
| Earnings from Continuing Operations | 73.41% | 25.13% | 11.75% | 12.46% | -8.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.41% | 25.13% | 11.75% | 12.46% | -8.57% |
| EBIT | 96.35% | 46.49% | 34.24% | 60.35% | 6.65% |
| EBITDA | 99.24% | 49.12% | 35.47% | 63.07% | 6.61% |
| EPS Basic | 88.65% | 30.39% | 24.58% | 45.01% | 43.70% |
| Normalized Basic EPS | 88.67% | 12.51% | 11.75% | 0.82% | 35.40% |
| EPS Diluted | 88.65% | 30.39% | 24.58% | 45.01% | 43.70% |
| Normalized Diluted EPS | 88.67% | 12.51% | 11.75% | 0.82% | 35.40% |
| Average Basic Shares Outstanding | 134.37% | 7.56% | 17.01% | 59.19% | 92.83% |
| Average Diluted Shares Outstanding | 134.37% | 7.56% | 17.01% | 59.19% | 92.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |